In our previous studies, we have differentiated interferon beta formulations for the treatment of MS using our clinical registry [5], and, separately, using routinely-collected healthcare data of the Campania Region of Italy [4,6], and showed that Rebif® might be characterized by better efficacy and healthcare utilization profile, when compared with other formulations. This evidence concerns the gene IFNB1 and myeloid sarcoma.